For tube feeding, our products (again, with the exception of Nutrition Shake) flow smoothly and without mechanical issues in the following enteral delivery systems: Infinity (by Moog), ePump, Joey (by Covidien), and Connect
Prior authorizations, insurance rejections, and coverage clarifications are more frequent for obesity indications
Industries that tend to have more generous benefits (pharma, technology, finance, regulated utilities) are more likely to offer coverage for GLP-1s, over industries with higher employee turnover like retail and hospitality
Below is a detailed explanation of how LPO products impact key oncogenic signalling pathways: A
Intraperitoneal administration of recombinant irisin activates the hippocampal PGC-1/FNDC5/BDNF signaling pathway, enhancing dendritic length and spine density in the CA1 and CA3 regions but not in the DG (Yang et al., 2015)
Secondly, the use of OGTT may not allow us to extend our findings to studies using meal challenge tests
